Mark Benedyk, Ph.D.
Dr. Benedyk is an Operating Partner for Sweetwater Capital Partners where he provides board support to Sweetwater’s direct and client Life Sciences portfolio companies and advises on Sweetwater Life Science investments. Prior to Sweetwater, he was President & CEO of Telephus Biosciences, a company developing innovative immunotherapies to treat drug-resistant infections. He is a director at Alafair Biosciences and at Pulmotect Inc. on behalf of Sweetwater client investors. Dr. Benedyk is also a director at Accel-Rx, Canada’s national biotech accelerator, and an advisor to RARE Science which applies genomics insights to accelerate cures for children with rare diseases. Previously, he was Head of The Pfizer Incubator LLC (TPI), Pfizer’s corporate incubator for early stage pharmaceutical companies. Dr. Benedyk has held executive business development roles at Ascenta, Optimer (now Merck NYSE: MRK), and Elan Pharmaceuticals (now Perrigo NYSE: PRGO). He received his Ph.D. in Developmental Genetics from The Rockefeller University, where he was a Lucille P. Markey Graduate Fellow and his B.S. degree in Microbiology and Botany from the University of Michigan.